Table 2.

Physician attitudes regarding once-weekly bortezomib.

Compared to twice-weekly bortezomib, once-weekly bortezomib….	Agree		Disagree		Unsure
	%	(n)	%	(n)	%	(n)
Has comparable durations of responses.	80%	(171)	5%	(11)	15%	(33)
Has lower rates of peripheral neuropathy.	90%	(194)	4%	(8)	6%	(14)
Is generally preferred by patients.	93%	(201)	2%	(5)	4%	(9)
Has inferior pharmacokinetics.	18%	(39)	45%	(97)	37%	(80)
Is harder to get regulatory approval for.	7%	(16)	55%	(118)	38%	(81)
Is inferior in acute cast nephropathy.	62%	(133)	16%	(34)	22%	(48)

Missing responses for any given question are not included.